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Abstract
A decline in β-cell function is a prerequisite for the development of type 2 diabetes, yet the
level of β-cell function in individuals at risk of the condition is rarely measured. This is due, in
part, to the fact that current methods for assessing β-cell function are inaccurate, prone to
error, labor-intensive, or affected by glucose-lowering therapy. The aim of the current study
was to identify novel circulating biomarkers to monitor β-cell function and to identify individu-
als at high risk of developing β-cell dysfunction. In a nested case-control study from the
Relationship between Insulin Sensitivity and Cardiovascular disease (RISC) cohort (n =
1157), proteomics and miRNA profiling were performed on fasting plasma samples from 43
individuals who progressed to impaired glucose tolerance (IGT) and 43 controls who main-
tained normal glucose tolerance (NGT) over three years. Groups were matched at baseline
for age, gender, body mass index (BMI), insulin sensitivity (euglycemic clamp) and β-cell
glucose sensitivity (mathematical modeling). Proteomic profiling was performed using the
SomaLogic platform (Colorado, USA); miRNA expression was performed using a modified
RT-PCR protocol (Regulus Therapeutics, California, USA). Results showed differentially
expressed proteins and miRNAs including some with known links to type 2 diabetes, such
as adiponectin, but also novel biomarkers and pathways. In cross sectional analysis at year
3, the top differentially expressed biomarkers in people with IGT/ reduced β-cell glucose
sensitivity were adiponectin, alpha1-antitrypsin (known to regulate adiponectin levels),
endocan, miR-181a, miR-342, and miR-323. At baseline, adiponectin, cathepsin D and
NCAM.L1 (proteins expressed by pancreatic β-cells) were significantly lower in those that
progressed to IGT. Many of the novel prognostic biomarker candidates were within the epi-
thelial-mesenchymal transition (EMT) pathway: for example, Noggin, DLL4 and miR-181a.
Further validation studies are required in additional clinical cohorts and in patients with type
2 diabetes, but these results identify novel pathways and biomarkers that may have utility in
monitoring β-cell function and/ or predicting future decline, allowing more targeted efforts to
prevent and intercept type 2 diabetes.
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Introduction
Type 2 Diabetes is a heterogeneous disease caused by insulin resistance, β-cell insufficiency or
a combination of both but the specific pathophysiology of the disease in the individual patient
is usually unknown.
Currently, methods of measuring β-cell function are inaccurate, prone to error, labor-
intensive, or affected by glucose-lowering therapy. For example, in the ADOPT study, the β-
cell function parameter HOMA-B was biased by the acute effects of glyburide, a sulfonylurea
that increases insulin secretion, in that a large apparent “improvement” in β-cell function in
the first year was followed by a sharp decline. During years 4 and 5 of the study, overall HbA1c
deteriorated much faster with glyburide than with metformin or rosiglitazone therapy while
HOMA-B remained stable [1].
Progression to type 2 diabetes is associated with a decline in β-cell function usually on a
background of long-standing insulin resistance [2–5]. Using current methodology it is not
possible to identify with an acceptable degree of certainty which prediabetic individuals have
the highest risk of progression. Whether they are classified as having impaired fasting glucose
(IFG) or impaired glucose tolerance (IGT), such individual have a definite impairment in β-
cell function, detected as a reduced acute insulin response to intravenous glucose or reduced
insulinogenic index in an oral glucose tolerance test (OGTT) [6, 7].
An important index of β-cell function is β-cell glucose sensitivity (the change in insulin
secretion rate for any given change in plasma glucose concentration), calculated by mathemat-
ical modeling of C-peptide concentrations following an oral glucose load [8]. This parameter
tracks quite accurately with β-cell function in longitudinal [9] as well as intervention studies
[10]; however, the requirement for a glucose challenge and multiple blood draws over a two-
hour period make it unsuitable for population studies or large scale trials of new drugs.
Novel prognostic biomarkers are therefore required to identify individuals at high risk of
decline in β-cell function. A validated set of novel biomarkers could enhance the accuracy of
disease prediction, provide novel insights into pathophysiology and contribute to future pre-
vention and interception of cases of the type 2 diabetes.
In the current study, we performed an unbiased screen of proteins and miRNAs in an estab-
lished longitudinal cohort (RISC) in which both insulin sensitivity and β-cell function were
well characterized at baseline [9, 11]. We compared individuals who developed IGT and exhib-
ited a decline in β-cell glucose sensitivity over three years of observational follow up with those
who remained NGT with stable β-cell glucose sensitivity. The aim was to identify proteins
and miRNAs that could potentially track β-cell function and predict future changes in β-cell
function.
Materials and methods
Cohort
We studied samples from the European RISC (Relationship between Insulin Sensitivity and
Cardiovascular Disease) cohort [7, 9, 11]. In brief, RISC is a longitudinal study of nondiabetic,
normotensive adults (n = 1384) characterized for both insulin sensitivity (hyperinsulinemic
euglycemic clamp) and β-cell function (multiple sampling OGTT with mathematical model-
ling) at baseline. Written consent was provided by all participants for their information to be
stored in the RISC database and used for research purposes, including exploratory biomarker
work. The study underwent appropriate review by the European Commission research pro-
gram and its ethics committee. The current retrospective analysis described did not require
additional review due to prior approval of future biomedical analyses at the time of initiation.
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At follow-up (3 years), multiple sampling OGTTs with mathematical modelling were com-
pleted, but the hyperinsulinemic euglycemic clamp was not repeated and insulin sensitivity
was calculated from the OGTT-derived parameter Oral Glucose Insulin Sensitivity index,
(OGIS) [12]. Among participants with normal glucose tolerance (NGT) at baseline (n = 1,157),
8% (n = 90) developed IGT at follow-up, which was associated with an average 40% decline in
β-cell glucose sensitivity and a 30% decline in insulin sensitivity. For our study, we selected 43
IGT individuals with the largest decline in β-cell glucose sensitivity at follow-up (cases) and 43
individuals experiencing no decline in β-cell glucose sensitivity (controls). Both groups were
matched at baseline for age, gender, BMI, waist-hip ratio, insulin sensitivity, family history of
diabetes, β-cell glucose sensitivity (Table 1).
Proteomics
1,129 proteins were measured from 75 μl of plasma using the multiplexed SomaLogic technol-
ogy according to SomaLogic’s proprietary method [13]. Briefly, DNA aptamers called SOMA-
mers (slow off-rate modified aptamers) were developed for each of the 1,129 proteins and
quantified using DNA microarray methodology. SOMAmers are protein recognition reagents
with high binding affinities and stable chemical structures. The plasma samples were incubated
with a mixture of SOMAmers to generate SOMAmer-protein complexes. Samples were then
cleared of unbound SOMAmers and proteins by two steps of stringent washing and bead-
based immobilization. SOMAmers were then eluted under high pH-denaturing conditions
and quantified by hybridizing to a DNA microarray. The SOMAmer mixture quantitatively
reflects the original protein concentration and results were provided in relative fluorescence
units (RFU).
miRNA profiling
RT-PCR based miRNA high-throughput detection according to Regulus Therapeutics’ propri-
etary method was used (http://regulusrx.com/) to measure 754 micro-RNAs. Briefly, 200 μl of
plasma is added to Qiagen spin columns and after an initial QC using specific miRNAs, the
solution is reverse transcribed using Megaplex RT primers, cDNA is amplified with Megaplex
preamp primers and loaded onto Open Array microRNA card and run using QuantStudio
Real Time PCR system. Data quality control and filtering were done by Regulus; for example,
miRNA assays with less than 20% detected values across samples were excluded. This left 203
miRNA for further analysis with values log-transformed to account for their non-normal
distribution.
Statistical analysis
Potential relationships with classification status, univariate statistics were initially calculated
between each predictor and responder classification. Specifically, the predictors were ranked
on their ability to distinguish cases from controls in order of ascending p-values on the basis of
unequal variance t-tests. While this approach can identify individual predictors that are associ-
ated with an outcome, it has the weakness of missing sets of predictors that may work in con-
junction with each other for outcome classification. A predictive modeling approach was
therefore used for predicting outcome classification.
Prior to modeling the data, several pre-processing steps were taken to avoid characteristics
that lead to model failure. These included the removal of near-zero variance predictors,
removal of highly correlated predictors, mean-centering and scaling of each predictor, and
imputation of missing predictor values as described in Kuhn and Johnson (2013) [14]. Several
predictive models were built to uncover relationships between predictors and cases and
Novel biomarkers of β-cell function
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controls. The models used for this data were: partial least squares, support vector machines,
recursive partitioning, and random forests. These models were specifically selected to be able
to uncover linear or complex non-linear separation between the outcome classes. Each of these
models has one or more tuning parameters. To select the optimal value of the tuning parame-
ters and to assess model classification performance, 5 repeats of 10-fold cross-validation were
used. Furthermore, because there were many more predictors than samples, recursive feature
elimination was used to eliminate predictors that were not associated with classification status
[14]. Recursive feature elimination prevents over-fitting to the data and selects only those pre-
dictors that are important for true hold-out sets.
The rank ordering of strength of each of the predictors for each of the models was aggre-
gated across models to generate a consensus view of predictor importance. We combined pre-
dictor importance information with the univariate statistics to identify predictors that were
not independently useful, but appeared to have utility when viewed in conjunction with other
predictors.
All relevant data are within the paper and its Supporting Information files.
Results
At baseline, cases and controls were well-matched for all anthropometric, clinical, and meta-
bolic characteristics (Table 1). At year 3, by design, cases had higher 2-hr OGTT plasma glu-
cose and lower β-cell glucose sensitivity; they also had higher fasting plasma glucose levels,
higher insulin concentrations, and significantly lower insulin sensitivity.
Diagnostic protein biomarkers of β-cell dysfunction
Cross-sectional analysis was performed at the 3-year time-point to identify differentially
expressed proteins reflective of current β-cell function. Following quality control procedures,
Somalogic data were available from 40 cases and 40 controls for 1,025 proteins. Univariate sta-
tistics identified 41 proteins differentially expressed (p<0.05) between cases and controls at
year 3 (Table 2 and S1 Table). In addition, a multivariate classification approach was used to
identify predictors that best separated cases from controls. Fourteen proteins were identified
Table 1. Demographic and clinical characteristics of the RISC cohort*.
Baseline p-value Follow-up p-value
Controls Cases Controls Cases
NGT/IGT 43/0 43/0 - 43/0 0/43 -
Familial diabetes 16/43 12/43 0.359 17/37 14/35 0.610
Age (years) 45.2 ± 7.5 44.8 ± 8.0 0.813
Sex (M/F) 17/26 18/25
BMI (kg/m2) 26.2 ± 3.7 26.2 ± 4.0 0.955 26.5 ± 3.6 26.8 ± 4.6 0.692
Waist-hip ratio 0.87 ± 0.07 0.87 ± 0.10 0.645 0.90 ± 0.07 0.90 ± 0.08
Fasting [G] (mmol/L) 4.93 ± 0.43 5.05 ± 0.36 0.186 5.13 ± 0.70 5.42 ± 0.53 0.036
2-hr [G] (mmol/L) 5.82 +/-1.00 6.20 +/-0.92 0.071 5.46 +/-1.12 8.57 +/-0.82 <0.001
Fasting [I] (pmol/L) 35 ± 18 39 ± 19 0.373 39 ± 19 49 ± 39 0.166
2-hr [I] (pmol/L) 196 ± 136 250 ± 244 0.248 195 ± 136 438 ± 378 <0.001
Insulin sensitivity (M) 114 ± 43 113 ± 56 0.906 ND ND -
OGIS (ml.min-1.kg-1) 11.1 ± 2.3 10.9 ± 1.9 0.666 11.6 ± 2.6 8.7 ± 2.6 <0.001
Glucose sensitivity 110 ± 41 110 ± 47 0.943 151 ± 74 83 ± 30 0.0000
* Entries are mean ± SD. [G] = plasma glucose concentration; [I] = plasma insulin concentration.
https://doi.org/10.1371/journal.pone.0182932.t001
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by all four predictive models; another 18 were identified by three of the four models. Low adi-
ponectin, a well-known biomarker linked with insulin resistance and β-cell function [15–18],
was a top diagnostic protein reflecting decline in β-cell glucose sensitivity by both multivariate
and univariate analysis (Fig 1). Histidine-rich glycoprotein (HRG), also highly ranked and
identified with lower plasma levels in cases in our analysis, is complexed with adiponectin in
human serum [19]. Endocan, a dermatan sulfate proteoglycan expressed in endothelial cells
and adipocytes and usually associated with inflammation [20], was highly ranked with
decreased plasma levels in cases at both baseline and at follow-up. Other proteins involved in
Table 2. Diagnostic predictors of β-cell function*.
Proteins miRNAs
Univariate FC Multivariate FC Univariate FC Multivariate FC
Adiponectin 0.76 FCG2A/B 1.44 miR-181a 0.18 miR-181a 0.18
kallikrein.5 1.14 Adiponectin 0.76 miR-323-3p 0.36 miR-323-3p 0.36
CHRDL1 0.88 Carbonic anhydrase III 1.38 miR-222 0.12 miR-342-3p 0.22
Endocan 0.85 sLeptin R 1.20 miR-483-5p 0.31 miR-151-5P 0.44
K.ras 1.14 Endocan 0.85 miR-454 0.34 miR-330 0.34
HRG 0.85 KI3S1 1.35 miR-151-5P 0.44 miR-454 0.34
a1.Antitrypsin 0.86 HRG 0.85 miR-330 0.34 miR-212 0.38
FCG2A.B 1.44 kallikrein 5 1.14 miR-652 0.23 miR-451 2.02
G.CSF.R 0.86 K-ras 1.14 miR-532-3p 0.46 miR-483-5p 0.31
Cystatin.M 0.85 CRDL1 0.88 miR-212 0.38 miR-136-star 0.55
IFN.lambda.2 0.86 NCAM-L1 0.91 miR-342-3p 0.22 miR-532-3p 0.46
Layilin 0.90 FCG3B 1.12 miR-136-star 0.55 miR-636 3.34
KI3S1 1.35 NRP1 0.92 miR-142-5p 0.52 miR-7 1.03
Cadherin.12 0.74 TNF sR-II 1.08 miR-433 0.52 miR-625-star 0.40
IGFBP-1 0.72 Cadherin-12 0.74 miR-204 0.56 miR-215 0.32
Aminoacylase.1 1.36 p27Kip1 1.33 miR-432 0.48 miR-432 0.48
Angiopoietin.4 0.90 IL-1b 0.84 miR-625-star 0.40 miR-30a-5p 1.00
RUXF 1.12 Carbonic anhydrase V 0.75 miR-451 2.02 miR-134 0.49
Kallikrein.4 0.89 HIPK3 1.24 miR-636 3.34 miR-30d 0.92
OSM 1.11 NKp30 1.25 miR-27b 0.26 miR-16 1.38
* Fold change (FC) is calculated as Case—Control. Entries in italics: Identified in 2 out of 4 predictive models.
https://doi.org/10.1371/journal.pone.0182932.t002
Fig 1. Scatterplot of diagnostic protein biomarkers. Circulating levels of top-ranked diagnostic biomarkers in IGT subjects (case, left)
compared to healthy controls (right).
https://doi.org/10.1371/journal.pone.0182932.g001
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inflammation such as sTNFR2 (increased), CD30 (TNF family, decreased), and kallikrein 5
(increased) were also differentially expressed. Carbonic anhydrase 3 (CA3) was highly ranked
in multivariate analysis, although only borderline significant in the univariate analysis with
reduced protein levels in cases. CA3 catalyzes the reversible hydration of carbon dioxide to
bicarbonate and is abundantly found in adipocytes, muscle, and liver [21].
Diagnostic miRNA biomarkers of β-cell dysfunction
miRNAs are important regulators of protein expression and are valuable as biomarkers due to
their stability in plasma. At year 3 in cross-sectional analysis, data were available from 40 cases
and 40 controls: 27 miRNAs were differentially expressed using univariate statistics (p0.05)
in cases vs. controls (Table 2 and S1 Table). Using multivariate analysis, 6 miRNAs were iden-
tified in all four predictive models and 9 miRNAs were identified in three models (S1 Table).
Thirteen of the 15 top diagnostic miRNAs identified in multivariate testing were in common
with the univariate list.
Full data were available from 38 cases and 38 controls for all measured protein biomarkers
and miRNAs for combined analysis with clinical covariates. Predictive models identified the β-
cell function parameter glucose during OGTT (gluO120, gluO90, gluO60), as the top predictor
(S3 Table). The top ranked non-OGTT predictors across the multivariate models were adipo-
nectin, kallikrein 5, CA3, sTNFR2, cadherin12, endocan, CRDL1 and miR-181a among others.
Prognostic protein biomarkers of β-cell dysfunction
Data were available at baseline and follow-up from 36 cases and 36 controls. Univariate statis-
tics identified 60 proteins differentially expressed (p0.05) between cases and controls at base-
line (Table 3 and S2 Table). A multivariate analysis with recursive feature elimination using
several different statistical methods allowed for the ranking of these proteins according to
importance. This analysis resulted in four proteins (adiponectin, noggin, DLL4, sialoadhesin)
ranking as important across all four models, while another 26 proteins were highly ranked in
three out of four models (Table 3 and S2 Table). We identified several proteins relevant to dia-
betes among the top ranked proteins at baseline. Adiponectin, was the highest ranked bio-
marker (by both multivariate and univariate analysis) of decline in β-cell glucose sensitivity
(Fig 2). Cathepsin D was also a top ranked predictor in both analyses, with protein levels
reduced in cases. Cathepsin D was shown in a recent prospective study using two other cohorts
to have a strong association with insulin resistance [22]. Other well-known diabetes-associated
molecules such as fibrinogen, IL-1 β and IL-6 were among other very highly ranked predictors.
NCAM-L1, Factor D (adipsin), CDK5-p35, endocan, noggin, DLL4 were identified as novel
potential prognostic biomarkers of β-cell function and were among the top ranked proteins.
A pathway analysis of baseline proteins with p-values< 0.05 using GeneGo (https://portal.
genego.com/) identified the epithelial-mesenchymal-transition (EMT) pathway as an impor-
tant differentially regulated pathway in cases vs. controls, and included proteins such as nog-
gin, DLL4, FGF12, GDF2 (BMP-9), and E-cadherin. Further down the prognostic list was
IGFBP-2, whose circulating levels were lower in cases at baseline. In men, low levels of IGFBP-
2 have been reported to be associated with metabolic syndrome [23].
Prognostic miRNA biomarkers of β-cell dysfunction
Data were available at baseline and follow-up from 40 cases and 40 controls. Differential
expression of 17 miRNAs with p-values at or below 0.05 in an unequal variance t-test compar-
ing controls to cases at baseline was identified (Table 3). Individuals that progressed to predia-
betes and reduced β-cell function exhibited a decrease in 16 of these 17 miRNAs, while
Novel biomarkers of β-cell function
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miR-497 was increased. Top differentially expressed miRNAs included miR-342-3p, miR-
181a, miR-590-3p, miR-497, and miR-25, whereas most abundant differentially expressed
miRNAs were miR-223, miR-483-5p, miR-375, miR-27b, and miR-222. Multivariate tests with
four predictive models identified two miRNAs (miR-181a and miR-590-3p) as important
across all four models with nine miRNAs in total identified as important in at least three of
these. All of these miRNAs were common between the univariate and multivariate list but the
rank ordering was different. miR-27b, miR-222 and miR-142-5p, among others, were ranked
higher in the multivariate list.
Table 3. Prognostic predictors of β-cell function*.
Proteins miRNAs
Univariate FC Multivariate FC Univariate FC Multivariate FC
Adiponectin 0.75 Adiponectin 0.75 miR-342-3p .25 miR-181a 0.21
Cathepsin.D 0.91 Noggin 0.82 miR-181a 0.21 miR-590-3P 0.55
NCAM.L1 0.87 DLL4 0.83 miR-590-3P 0.55 miR-27b 0.26
Factor.D 0.91 Sialoadhesin 1.20 miR-497 1.49 miR-222 0.23
CDK5.p35 0.91 CDK5/p35 0.91 miR-25 0.14 miR-323-3p 0.46
Endocan 0.85 COLEC12 0.89 miR-323-3p 0.46 miR-151-5P 0.53
Coagulation.Factor.XI 0.89 FGF-12 1.08 miR-151-5P 0.53 miR-142-5p 0.61
Cystatin.M 0.84 Cathepsin D 0.91 let-7c 0.67 miR-625-star 0.42
MIS 0.90 P-Cadherin 0.91 miR-27b 0.26 miR-205 0.66
Fibrinogen 0.91 NCAM-L1 0.87 miR-483-5p 0.37 miR-342-3p 0.25
CHL1 0.91 C1QBP 0.93 miR-625-star 0.42 miR-223 0.11
SCF.sR 0.89 TNFSF18 0.96 miR-205 0.66 miR-331 1.41
Carbonic.Anhydrase.IV 0.91 Coagulation Factor XI 0.89 miR-532-3p 0.53 miR-497 1.49
MM1 1.39 TCCR 0.89 miR-375 0.53 let-7g 0.39
PAK3 0.92 IL-11 0.87 miR-223 0.11 miR-211 0.56
ARGI1 0.93 Layilin 0.91 miR-222 0.23 miR-652 0.38
Noggin 0.82 IL-1b 0.80 miR-142-5p 0.61 miR-375 0.53
GDF2 0.77 Endocan 0.85 miR-125b 0.83
DLL4 0.83 Factor D 0.91 miR-378-1 1.52
IL.6 1.27 Semaphorin 3A 0.83 miR-532-3p 0.53
* Fold change (FC) is calculated as Case—Control. Entries in italics: Identified in 2 out of 4 predictive models.
https://doi.org/10.1371/journal.pone.0182932.t003
Fig 2. Scatterplot of prognostic protein biomarkers. Circulating levels of top-ranked prognostic biomarkers in IGT subjects (case, left)
compared to healthy controls (right).
https://doi.org/10.1371/journal.pone.0182932.g002
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Prognostic protein and miRNA biomarkers of β-cell dysfunction
Combined data were available from 35 cases and 35 controls for all measured protein biomark-
ers and miRNAs for combined analysis with clinical covariates Predictive models identified
2-hr plasma insulin levels and potentiation as the highest rank predictors of future β-cell func-
tion (S3 Table). Potentiation is a time-dependent factor that characterizes an aspect of β-cell
function aspect distinct from β-cell glucose sensitivity [24]. The top protein predictors were
adiponectin and then FGF12, cathepsin D, STK16, DLL4 and CD30. The top miRNA biomark-
ers were miR-342-3p, miR-181a, and miR-590-3p (S3 Table). The top prognostic biomarkers
between the univariate analysis and multivariate analyses were very similar with mainly differ-
ences in the rank order.
Overlap of diagnostic and prognostic biomarkers
While only 12 of 77 protein biomarkers (16%) identified in the diagnostic list (univariate)
were also differentially expressed at baseline and identified as prognostic biomarkers (Fig 3),
this was the case for 50% of the top 20 miRNAs (Fig 4).; For example, the four top miRNAs
from the diagnostic (multivariate) list (miR-181a, miR-323-3p, miR-342-3p, and miR-151-5p)
were also differentially expressed at baseline. These miRNAs are respectively involved in
hepatic insulin sensitivity (miR-181a) [25], expressed in human β-cells (miR-323-3p) [26],
identified in PBMCs from people with diabetes (miR-342-3p) [27], and regulated by exercise
(miR-151-5p) [28]. At follow-up, miR-330, miR-454, and miR-212 among others were selec-
tively changed (Fig 4). Of the 12 proteins differentially expressed at both baseline and follow-
up, six (adiponectin, endocan, coagulation factor XI, cystatin M, CHL1, and SCF-sR) were in
the top 20 prognostic list and seven (adiponectin, CRDL1, endocan, HRG, alpha1-antitrypsin,
Fig 3. Venn diagram of prognostic and diagnostic protein predictors based on the univariate analysis with p<0.05. Twelve
proteins were identified as differentially expressed at both time-points; 48 proteins were only predictive at baseline; and 29 only at follow-
up. Proteins in bold were among top 20 in both prognostic and diagnostic lists.
https://doi.org/10.1371/journal.pone.0182932.g003
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FCG2A/B, and cystatin M) were in the top 20 of the univariate diagnostic list (Fig 3). Five pro-
teins were found in both the multivariate prognostic and diagnostic lists; adiponectin, siaload-
hesin, NCAM-L1, IL-1 β and endocan (Tables 2 and 3).
Discussion
The current study used plasma proteomics and miRNA profiling in samples obtained from the
longitudinal RISC study to identify prognostic and diagnostic protein and miRNA biomarkers
predicting or reflecting β-cell glucose sensitivity. Several protein biomarkers were identified
reflecting decline in β-cell glucose sensitivity at follow-up that also showed value to distinguish
cases from controls at baseline, even although groups were well matched for glucose tolerance,
insulin sensitivity, and β-cell glucose sensitivity (as well as standard clinical covariates). At the
top of the list of proteins identified, adiponectin, endocan, and sialoadhesin were of particular
interest as they show potential value in both monitoring and predicting future decline in β-cell
function. However, a novel finding was the implication of both proteins and miRNAs within
the EMT pathway as differentially expressed at baseline in those that progressed to IGT and
reduced β-cell function. EMT is, among other functions, prominent during formation of endo-
crine cells in the pancreas in embryogenesis [29].
Adiponectin is known to regulate glucose levels and fatty acid breakdown and to enhance
insulin sensitivity in muscle and liver [30]. Our results implicate low baseline plasma adipo-
nectin levels in healthy individuals as a predictor of future β-cell dysfunction and IGT. We
observed a 0.74-fold decrease in plasma adiponectin in individuals who progressed to worse β-
cell glucose sensitivity and IGT. These data are corroborated by a recent longitudinal study in
which individuals who progressed from NGT to prediabetes/diabetes had lower baseline adi-
ponectin (8.4±4.0 μg/mL) compared to non-progressors (9.9±5.8 μg/mL) [31]. Another recent
study in non-obese individuals at risk for diabetes demonstrated a negative association
between baseline adiponectin and change in 2-hr plasma glucose, fasting insulin, HOMA-IR
and HOMA- β [32]. In a further study, the resistin-adiponectin ratio (RA index) was strongly
associated with β-cell function—assessed by OGTT-derived indices—in two NGT cohorts
with different degrees of overweight/obesity [33]. The authors suggested that waist-hip ratio is
a strong modulator of β-cell function [33] but in the present study neither waist-hip ratio nor
Fig 4. Venn diagram of prognostic and diagnostic miRNA predictors based on the univariate analysis
with p<0.05. 11 miRNAs were identified as differentially expressed at both time-points; 6 miRNAs were
predictive of ß-cell glucose sensitivity at baseline only; and 16 only at follow-up.
https://doi.org/10.1371/journal.pone.0182932.g004
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resistin had predictive value. Previous analyses of the RISC cohort using 1017 baseline samples
showed adiponectin levels were positively associated with insulin sensitivity and HDL-choles-
terol, partly explaining how low plasma concentrations of adiponectin predict insulin resis-
tance [15, 16]. Alpha1-antitrypsin (α1-AT), another candidate biomarker found in our studies
with lower plasma levels in cases both at baseline and follow-up, is a serine proteinase inhibitor
associated with type 2 diabetes [34–36] which amongst other effects inhibits the enzymatic
activity of neutrophil elastase (NE) (which degrades adiponectin) and cathepsin G.
Several of the top prognostic proteins and miRNA we identified are functional in pancreatic
islets [37]. In addition, our results are in keeping with those of a very recent study describing
cathepsin D as a marker of insulin resistance [22]; moreover, cathepsin D expression is
reduced in islets from people with type 2 diabetes [38]. CDK5 was another islet protein identi-
fied in our proteomics screen to predict β-cell dysfunction: when over-activated by glucose it
suppresses insulin gene expression [39, 40]. Conversely, decreased CDK5 activity enhances
glucose-stimulated insulin secretion (GSIS) [40]. With regard to the top 20 miRNAs we identi-
fied, both miR-27b and miR-375 are abundant in human islets [41–43]. ADIPOR2 is a con-
firmed target for miR-375 [44] and miR-323-3p is enriched in human β-cells compared to α-
cells [26]. miR-212 was expressed at follow-up but not at baseline. Silencing of miR-212
reduced, and overexpression increased, GSIS [45]; moreover, miR-212 was significantly up-
regulated by GLP-1 (>2-fold) in isolated rat, mouse, and human islets [46].
Noggin, which was lower in cases vs controls, is a bone morphogenetic protein (BMP)
antagonist shown to induce differentiation of embryonic stem cells into pancreatic and endo-
crine lineages [47]. DLL4 (Delta-like ligand 4) is a Notch ligand that suppresses the Delta-
Notch signaling pathway and is permissive for pancreatic endocrine development [48]. GDF2
(BMP9 is the protein encoded by GDF2), which was high on the list of proteins predictive of
decline in β-cell glucose sensitivity, has been shown to improve glucose homeostasis in both
diabetic and nondiabetic rodents by acting on hepatocytes and myotubes [49, 50]. P-cadherin
and E-cadherin, both lower in cases than controls, are modulated during EMT when epithelial
cells lose their characteristics [51]. NCAM-L1, also lower in cases, can remodel extracellular
matrix and has been found to be elevated in type 2 diabetes people with retinopathy [52].
An unexpected number of prominent prognostic predictors were in the EMT pathway, a
conserved pathway in which epithelial cells lose their characteristics and start migrating as
mesenchymal cells [29]. During EMT, tissue is remodelled via highly regulated gene expres-
sion such that epithelial cells lose their cell-cell junctions, apical-basal polarity and re-organize
their cytoskeleton. Our data implicate proteins in the EMT pathway as novel potential prog-
nostic and insulin-independent biomarkers for predicting decline in human β-cell function.
miRNAs with known functions in the EMT pathway were also differentially expressed at base-
line and correlated with a change in β-cell glucose sensitivity: miR-181a, which was top rank-
ing at both baseline and follow-up, has been shown to regulate Prox1, which also is associated
with EMT regulation [53]. In addition, Prox1 has been reported to have a strong association
with diabetes [54–56]. miR-181a is a target for Fatty Acid Desaturase 1 (FADS1), a prominent
genetic hit in AMP-Portal (http://www.type2diabetesgenetics.org). miR-205 is markedly
downregulated in cells that have undergone EMT in response to transforming growth factor
(TGF)- β or to ectopic expression of the protein tyrosine phosphatase Pez [57]. Inhibition of
the miRNAs (miR-205 and others) was sufficient to induce EMT in a process requiring upre-
gulation of ZEB1 and/or SIP1 [57]. ZEB1 represses E-cadherin [57] and induces expression of
BMP antagonists such as Noggin and chordin-like 1 (CRDL1, CHRDL1) [58], which were
highly ranked at baseline and follow-up, respectively. miR-497, the only prognostic miRNA
with higher expression in cases, has higher expression levels in type 2 diabetes Goto-Kakizaki
(GK) vs Wistar control rat islets [59]. In muscle cells, Igfr and Insr genes are direct targets of
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miR-497, which downregulates their expression [60]. Interestingly, miR-497 expression has
also been shown to inhibit EMT in breast carcinoma by targeting Slug [61].
Until recently, most EMT regulation in the pancreas has been described in either the devel-
oping pancreas or regeneration models, such that β-cells become dedifferentiated and revert to
a progenitor-like stage [62]. There is also evidence that rodent β-cells can partly convert to
other endocrine cell types. By using a new marker for endocrine progenitor cells, aldehyde
dehydrogenase 1A3 (ALDH1A3), Cinti et al. [63] recently showed a three-fold increase in cells
positive for this marker and negative hormone staining in islets from type 2 diabetes donors
compared to healthy controls. Islets from those with type 2 diabetes expressed β-cell-specific
markers mislocalized to α-cells and δ-cells. Another recent study linked β-cell glucose sensitiv-
ity to insulin/glucagon bihormonal cells in nondiabetic insulin resistant humans [64].
Two other high-ranking proteins worthy of attention are endocan and carbonic anhydrase
3 (CA3). Endocan (also known as endothelial-cell specific molecule-1, ESM-1) identified here
as lower in cases at both baseline and follow-up, is a soluble proteoglycan secreted by vascular
endothelial cells. In adipocytes, endocan production is inhibited by insulin and cortisol, and
circulating endocan levels have been found to be reduced in overweight and obese women
[65], in insulin resistant [66] and in type 2 diabetes patients [67]. Endocan is also involved in
other diseases such as chronic kidney disease, hypertension, and coronary artery disease [68].
Besides CA3, we observe several carbonic anhydrases (CA4 prognostic, CA3 and CA6 diagnos-
tic) that show differential expression in cases vs controls. These enzymes regulate intracellular
pH, and decreased CA3 levels have also been proposed to play a role in muscle fatigue and to
lead to decreased ATP synthesis in mitochondria [69]. Obese animal models have decreased
CA3 activity and concentration in white adipose tissue [21, 70].
With regard to pro-inflammatory biomarkers, higher baseline interleukin-6 (IL-6) levels
have been reported to be associated with increased fasting insulin, insulin resistance, and β-
cell function in the nondiabetic Whitehall II study cohort, while higher baseline adiponectin
levels were associated with decrements in fasting glucose and insulin [71]. In our analysis, IL-6
was a univariate prognostic predictor in cases vs controls (Table 3). Other pro-inflammatory
proteins emerging from our data were sTNFR2 and CD30, which are part of the TNF family
(sTNFR2 up and CD30 down). TNFα signaling causes free fatty acid levels to rise via increased
adipocyte lipolysis and downregulation of insulin signaling [72]. Increased sTNFR2 has been
found in first-degree relatives of insulin resistant diabetic subjects [73] and in children with
IGT [74], and was independently associated with increased aortic stiffness and pulse wave
velocity in type 2 diabetes [75]. Both sTNFR1 and sTNFR2 have been shown to predict pro-
gression of kidney disease in both type 1 and type 2 diabetes [76, 77].
In summary, the current study is the first to have measured a large number of proteins and
miRNAs in a case-control cohort of nondiabetic subjects matched not only on anthropo-
metrics but also on the basis of careful physiological measurements of glucose tolerance, i.e.,
insulin sensitivity and β-cell function. Our results show that low adiponectin is strongly associ-
ated with β-cell dysfunction and is the top predictor of incident IGT. In addition, several pro-
teins and miRNAs in the EMT pathway predicted a decline in β-cell function and glucose
tolerance. While this biomarker discovery approach requires further validation in independent
clinical cohorts, our data strongly suggest that the EMT pathway may in the near future pro-
vide useful biomarkers of β-cell function (and its decline) as well as potential new therapeutic
targets. Novel circulating biomarkers that reflect or predict β-cell function could transform the
way we treat type 2 diabetes, allowing for a more targeted and personalized approach, and
potentially contribute to preventing its development entirely.
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